Evercore ISI lowered the firm’s price target on Natera (NTRA) to $250 from $260 and keeps an Outperform rating on the shares as part of the firm’s medical technology and life science tools Q1 preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera Expands Board, Appoints Eric Rubin as Director
- IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Diversification and Growth to Investors
- Natera announces publications on clinical utility of Signatera
- GeneDx data could support improved coverage, says Craig-Hallum
- Natera announces commercial launch of Zenith genomics